Salt Lake City, Utah, United States
NCT Number: NCT02414919
Duration of Use of Highly Effective Reversible Contraception
To assess the proportion of women who use HERC for ≥2 years of duration
Looking for future studies?
Notify MeKey information
Conditions
Age range
15 year–44 year
Sex eligibility
Female
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012
Treatment and study plan
Mirena (Levonorgestrel IUS, BAY86-5028)
DrugLevonorgestrel-releasing intrauterine device 20 mcg/day
ParaGard
DrugCopper T380A
Implanon/Nexplanon
DrugEtonorgestrel contraceptive implant
Primary outcomes
-
Proportion of women who use HERC
Time frame: 2 years post-HERC initiation
Secondary outcomes
-
Duration of real world use of three different HERC devices
Time frame: 2 years post-HERC initiation
Other outcomes
-
Difference in patient characteristics of women who chose different HERC devices
Time frame: 2 years post-HERC initiation
-
Proportion of HERC used for ≥3 years of duration
Time frame: ≥3 years post-HERC initiation
-
Model the predictors of ≥3 years of duration
Time frame: ≥3 years post-HERC initiation
Sponsors and collaborators
Lead sponsor
Bayer
Industry
Collaborators
- University of Utah
Registry information
Official study title
Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Apr 13, 2015
- Registry last updated
- Mar 16, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Multiple Micronutrient Versus Iron-Folic Acid Supplementation in Pregnant Women in Indonesia
NCT07725549
Birth Weight, Body Weight
Purwodadi Grobogan, Central Java, Indonesia
View Trial DetailsEvaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria
NCT02447159
Behavior, Blood-Borne Infections
Eket, Akwa Ibom State, Nigeria
View Trial DetailsChildbirth Education Classes, Spousal Support, Birth Memory, Choice of the Birth Method, and Birth Satisfaction
NCT07072507
Birth, Birth Memory
Bursa, Turkey (Türkiye)
View Trial DetailsClinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes (Philani Ndiphile)
NCT04446611
Acquired Immunodeficiency Syndrome, Antenatal Care
East London, Eastern Cape, South Africa
View Trial Details